Hodge, et al. U.S. Appl. No. 10/531,630 Second Preliminary Amendment Page 11

REMARKS

The Specification has been amended to refer to the prior applications (37 CFR 1.78). Claim 19 has been amended. Support for the amendment of claim 19 may be found, *inter alia*, on page 5, lines 26-27. Entry of this Amendment is respectfully requested.

4-(3-(2,6-Dimethylbenzyloxy)phenyl)-4-oxobutyric acid is metabolized in mice, rats, dogs and humans to 4-(3-(2,6-Dimethylbenzyloxy)-phenyl)-4-hydroxybutanoic acid and 3-(2,6-Dimethylbenzyloxy)-phenylacetic acid. The administration of 4-(3-(2,6-Dimethylbenzyloxy)phenyl)-4-oxobutyric acid to treat certain metabolic disorders is disclosed in WO 02/100341 (Wellstat Therapeutics Corp.).

Respectfully submitted,

Lewis J. Kreisler Reg. No. 38522

Attorney for Applicant(s)

930 Clopper Road Gaithersburg, MD 20878 Phone: (240) 631-2500 x3276 Facsimile: (240) 683-3794